These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1086 related items for PubMed ID: 31243569

  • 1. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 2. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
    [Abstract] [Full Text] [Related]

  • 4. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
    Lindsay J, Othman J, Yong MK, Ritchie D, Chee L, Tay K, Tio SY, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SC, Kong DCM, Greenwood M, Pergam SA, Liu C, Slavin MA.
    Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
    [Abstract] [Full Text] [Related]

  • 5. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
    [Abstract] [Full Text] [Related]

  • 6. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 7. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
    [Abstract] [Full Text] [Related]

  • 9. Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center.
    Dogan B, Sema YA, Bora K, Veysel U, Benan D, Ezgi KT, Gozde AK, Demir D, Ozsan N, Hekimgil M, Zumrut SB, Miray K, Funda C, Sema A.
    J Med Virol; 2024 Jun; 96(6):e29767. PubMed ID: 38932460
    [Abstract] [Full Text] [Related]

  • 10. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 11. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE, Mocroft A, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Iversen M, Kirkby NS, Rasmussen A, Sørensen SS, Lundgren JD, MATCH in PERSIMUNE study group.
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [Abstract] [Full Text] [Related]

  • 12. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, Wang FR, Zhao T, Liu YR, Liu KY, Huang XJ.
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2185-2191. PubMed ID: 26253005
    [Abstract] [Full Text] [Related]

  • 14. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, Toffoletti E, Dozzo M, Michelutti A, Gregoraci G, Geromin A, Cerno M, Savignano C, Rinaldi C, Barbone F, Fanin R.
    Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
    Kinch A, Hallböök H, Arvidson J, Sällström K, Bondeson K, Pauksens K.
    Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836
    [Abstract] [Full Text] [Related]

  • 16. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors.
    Wang N, Wang H, Fang S, Du J, Huang S, Li F, Jin X, Jia M, Xu L, Dou L, Liu D.
    Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670
    [Abstract] [Full Text] [Related]

  • 17. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L.
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Aug; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 19. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
    Weng G, Fan Z, Xue H, Huang F, Xu N, Jin H, Yu S, Ye Z, Fan J, Xuan L, Liu Q.
    Front Immunol; 2022 Aug; 13():1036403. PubMed ID: 36389692
    [Abstract] [Full Text] [Related]

  • 20. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A, Liu Y, Walker JT, Fonseca K, Daly A, Duggan P, Stewart D, Russell JA, Storek J.
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.